

Selected BMS studies at the 2024 ASH Annual Meeting and Exposition include:

Abstract Title	Author	Presentation Type/#	Session Title	Session Date/Time (PST)
<i>Autoimmune Disease</i>				
Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies	Fabian Müller	Poster Presentation #2088	Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I	Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET)
<i>Acute Myeloid Leukemia (AML)</i>				
Synergistic Activity of BMS-986397, a First-in-Class α Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1 α (CK1 α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)	Carmen Jimenez	Poster Presentation #1395	Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I	Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET)
<i>Beta Thalassemia</i>				
Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β -Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE Trial	John Porter	Poster Presentation #2475	Session: 112. Thalassemia and Globin Gene Regulation: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
Luspatercept Improves Fatigue-Related Quality of Life through 5 Years of Treatment in Non-Transfusion Dependent Beta-Thalassemia	Khaled Musallam	Poster Presentation #3857	Session: 112. Thalassemia and Globin Gene Regulation: Poster III	Monday, December 9, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
<i>Lymphoma</i>				
Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment	Ash Alizadeh	Oral Presentation #72	Session: 628. Aggressive Lymphomas: Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas	Saturday, December 7, 2024: 10:45 AM (1:45 PM ET)

(tx) from the Phase 3, Randomized TRANSFORM Study				
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry	Maria Silvina Odstrcil Bobillo	Oral Presentation #470	Session: 626. Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma	Sunday, December 8, 2024: 9:45 AM (12:45 PM ET)
Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry	Sairah Ahmed	Oral Presentation #472	Session: 626. Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma	Sunday, December 8, 2024: 10:15 AM (1:15 PM ET)
Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)	Arnaud Amzallag	Oral Presentation #579	Session: 627. Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL	Sunday, December 8, 2024: 12:30 PM (3:30 PM ET)
Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study	Julio C. Chavez	Poster Presentation #3018	Session: 623. Mantle Cell, Follicular, Waldenströms, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)	Jeremy Abramson	Poster Presentation #3125	Session: 628. Aggressive Lymphomas: Cellular Therapies: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up	Jeremy Abramson	Poster Presentation #3130	Session: 628. Aggressive Lymphomas: Cellular Therapies: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)

Degradation of Ikaros Induces Neutropenia through Altered Transcriptional Programming across Multiple Stages of Neutrophil Development and Maturation	Ajit Dhadve	Poster Presentation #2523	Session: 201. Granulocytes, Monocytes, and Macrophages: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)	Alexander P. Boardman	Poster Presentation #3028	Session: 623. Mantle Cell, Follicular, Waldenström, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)	Jean-Marie Michot	Oral Presentation #869	Session: 627. Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications	Monday, December 9, 2024: 3:45 PM (6:45 PM ET)
Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study	William Wierda	Oral Presentation #887	Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease- Novel Agents and Quality-of-Life	Monday, December 9, 2024: 3:45 PM (6:45 PM ET)
Deciphering the Mechanism of Action of the Novel CELMoD™, Golcadomide, during Germinal Center B Cell Immune Response and in a Preclinical Mouse Model of Follicular Lymphoma	Caroline Huber	Oral Presentation #955	Session: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma	Monday, December 9, 2024: 4:30 PM (7:30 PM ET)
BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degradator (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin's Lymphoma	Lynda Groocock	Oral Presentation #957	Session: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma	Monday, December 9, 2024: 5:00 PM (8:00 PM ET)
Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic	Tanya Siddiqi	Poster Presentation #4633	Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III	Monday, December 9, 2024: 6:00 PM-8:00 PM

Lymphoma (SLL): Updated Follow-up of Transcend CLL 004				(9:00 PM-11:00 PM ET)
Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up	Loretta J. Nastoupil	Poster Presentation #4387	Session: 623. Mantle Cell, Follicular, Waldenström, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III	Monday, December 9, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
<i>Multiple Myeloma</i>				
Iberdomide, Daratumumab, and Dexamethasone Shows Deep Antimyeloma Activity across Molecular Patient Subsets with Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the CC-220-MM-001 Trial	Michael Amatangelo	Poster Presentation #1973	Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster I	Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET)
BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CART Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results	Susan Bal	Poster Presentation #2069	Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I	Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET)
Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial	Luciano Costa	Oral Presentation #677	Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond	Sunday, December 8, 2024: 5:30 PM (8:30 PM ET)
Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide	Tracy Chow	Poster Presentation #3261	Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up	Barry Paul	Poster Presentation #3388	Session: 655. Multiple Myeloma: Cellular Therapies: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
Global Manufacturing Experience with Idecabtagene Vicleucel in Patients with Relapsed and Refractory Multiple Myeloma	Surbhi Sidana	Poster Presentation #3476	Session: 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)

Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis	Maria Chaudhry	Poster Presentation #3382	Session: 655. Multiple Myeloma: Cellular Therapies: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (R/R) Multiple Myeloma	Susan Bal	Oral Presentation #922	Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies	Monday, December 9, 2024: 3:30 PM (6:30 PM ET)
Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial	Irwindeep Sandhu	Oral Presentation #1025	Session: 654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma	Monday, December 9, 2024: 5:30 PM (8:30 PM ET)
<i>Myelodysplastic Syndromes</i>				
The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe	Maria Diez-Campelo	Oral Presentation #118	Session: 908. Outcomes Research: Myeloid Malignancies: Identifying Problems and Providing Solutions to Delivering Myeloid Malignancy Care	Saturday, December 7, 2024: 10:15 AM (1:15 PM ET)
Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent-Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial	Guillermo Garcia-Manero	Oral Presentation #350	Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS	Saturday, December 7, 2024: 4:15 PM (7:15 PM ET)
Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS Trial	Valeria Santini	Poster Presentation #1818	Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I	Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET)

Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial	Guillermo Garcia-Manero	Poster Presentation #1832	Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I	Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET)
Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia	Pramila Krishnamurthy	Poster Presentation #2425	Session: 908. Outcomes Research: Myeloid Malignancies: Poster I	Saturday, December 7, 2024: 5:30 PM-7:30 PM (8:30 PM-10:30 PM ET)
Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study	Esther N. Oliva	Poster Presentation #3216	Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain	Maria Diez-Campelo	Poster Presentation #5055	Session: 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III	Monday, December 9, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
BMS-986397, a First-in-Class Molecular Glue Degradator of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53	Carmen Jiminez	Poster Presentation #4142	Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III	Monday, December 9, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
<i>Myelofibrosis</i>				
Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial	Haifa Kathrin Al-Ali	Oral Presentation #482	Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents	Sunday, December 8, 2024: 9:45 AM (12:45 PM ET)
Burden and Clinical Outcomes in Patients (pts) with Myelofibrosis (MF) and Anemia Treated with Ruxolitinib (RUX): Data from the Veterans Affairs Corporate Data Warehouse (VACDW)	John O. Mascarenhas	Poster Presentation #3807	Session: 908. Outcomes Research: Myeloid Malignancies: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)
<i>Sickle Cell Disease</i>				

Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease	Emily Rychak	Oral Presentation #169	Session: 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Identification of New Molecular Targets to Modulate Sickle Cell Disease	Saturday, December 7, 2024: 2:00 PM (5:00 PM ET)
Rap-536, a Murine Luspatercept Analog Ameliorates Anemia and Vaso-Occlusion in Experimental Model of Sickle Cell Disease	Thiago T. Maciel	Oral Presentation #621	Session: 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Attenuating Sickle Cell Disease Complications: Lessons from Pre-clinical Models	Sunday, December 8, 2024: 5:00 PM (8:00 PM ET)
<i>Thrombosis and Anticoagulation</i>				
Reversal of The Anticoagulant Effect of Milvexian by 4-Factor PCC and rFVIIa in Healthy Participants*	Victor Dishy	Poster Presentation #2628	Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II	Sunday, December 8, 2024: 6:00 PM-8:00 PM (9:00 PM-11:00 PM ET)